RPRX PEER ANALYSIS

Royalty Pharma Plc — metric-by-metric comparison with peers and the industry median

RPRXRoyalty Pharma Plc

🇺🇸 USA · NASDAQ · Healthcare · Biotechnology

Value it Duel

Overall Profile & Returns

· Biotechnology

Position Within Industry

0 = weak quartile, 100 = strong quartile

RPRXIndustry median

Scores normalize each metric against industry quartiles (p25–p75); direction is inverted for lower-is-better metrics.

Return Comparison

1-Year

Split-adjusted

Year-to-Date (YTD)

Key Metric Comparison

P/E

Lower is better

ROE

Higher is better

Net Margin

Higher is better

Revenue Growth

Higher is better

All Metrics

Valuation
Metric	RPRX	CSL	TLX	MSB	Ind. Median
P/E	39.08	29.96●	—	—	18.06
P/B	4.70	2.24●	6.38	—	3.62
EV/EBITDA	23.95	10.35●	120.20	—	15.13
P/S	13.25	2.66●	3.24	31.30	10.65

Financial Health
Metric	RPRX	CSL	TLX	MSB	Ind. Median
Current Ratio	2.66●	2.57	1.43	—	5.90
Debt/Equity	130.0%	67.4%●	112.3%	—	10.9%
NetDebt/EBITDA	4.91	2.22●	13.13	—	1.15

Profitability
Metric	RPRX	CSL	TLX	MSB	Ind. Median
Net Margin	33.9%●	9.2%	-0.9%	-115.3%	-125.7%
ROE	12.2%●	7.7%	-1.8%	-11.3%	-47.5%
ROA	4.4%●	3.8%	-0.7%	-8.6%	-35.8%
EBITDA Margin	69.6%●	32.8%	3.0%	-76.6%	-105.8%

Growth + Dividend
Metric	RPRX	CSL	TLX	MSB	Ind. Median
Rev. Growth	7.8%	4.8%	56.3%	410.4%●	5.1%
NI Growth	-24.3%●	-39.4%	—	—	12.1%
Div. Yield	1.6%	2.5%●	—	0.0%	0.2%
Payout	46.8%	103.1%	—	0.0%	0.0%

Valuation
Metric	RPRX	MRNA	ROIV	RVMD	ALNY	INCY	Ind. Median
P/E	39.08	—	—	—	77.01	17.05●	18.06
P/B	4.70	4.25●	6.51	25.15	41.34	4.40	3.62
EV/EBITDA	23.95	—	—	—	46.21	10.92●	15.13
P/S	13.25	14.16	3,570.72	—	10.37	4.55●	10.65

Financial Health
Metric	RPRX	MRNA	ROIV	RVMD	ALNY	INCY	Ind. Median
Current Ratio	2.66	2.41	18.37●	6.80	3.13	3.68	5.90
Debt/Equity	130.0%	17.5%	2.4%	29.2%	118.4%	0.6%●	10.9%
NetDebt/EBITDA	4.91	1.35	16.03	1.12	-1.88	-2.13●	1.15

Profitability
Metric	RPRX	MRNA	ROIV	RVMD	ALNY	INCY	Ind. Median
Net Margin	33.9%●	-143.6%	-3,629.2%	—	13.5%	26.7%	-125.7%
ROE	12.2%	-36.6%	-6.5%	-76.7%	96.9%●	31.1%	-47.5%
ROA	4.4%	-26.4%	-5.4%	-59.4%	12.4%	21.9%●	-35.8%
EBITDA Margin	69.6%●	-129.7%	-3,162.6%	—	21.6%	34.9%	-105.8%

Growth + Dividend
Metric	RPRX	MRNA	ROIV	RVMD	ALNY	INCY	Ind. Median
Rev. Growth	7.8%	-29.1%	-67.7%	-100.0%	82.6%●	21.5%	5.1%
NI Growth	-24.3%	—	—	—	—	6,631.4%●	12.1%
Div. Yield	1.6%	—	—	—	—	—	0.2%
Payout	46.8%	—	—	—	—	—	0.0%

The green dot marks the best value in the group given the metric direction (higher/lower is better). All metrics use trailing-twelve-month (TTM) data.

Go deeper on RPRX

Run a DCF valuation

Full DCF model with editable assumptions

Start a head-to-head duel

Compare two stocks metric by metric

Filter in the stock screener

Build your own universe with 400+ metrics

Data on this page refreshes once per day. Price data as of Jul 7, 26. This content is for informational purposes only and is not investment advice.